Article
CAR-T-drug conjugate against solid tumor
2026-01-02
Abstract excerpt
Chimeric antigen receptor (CAR)-T cell therapy has been clinically successful in hematologic cancers but faces challenges in solid tumors, primarily due to limited tumor infiltration, immunosuppressive tumor microenvironments (TME), and antigen heterogeneity. While combining CAR-T cell therapy with chemotherapy can enhance antitumor activity, this often leads to substantial systemic toxicity. In this study, we int...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 85171c9b-7e10-50d3-9b4f-406c81098cfb
- DOI
- 10.64898/2026.01.02.696502
